Adicet Bio

Adicet Bio

Yahoo Finance • 17 days ago

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Adicet Bio, Inc. (ACET) is a stock that can certainly grab the attention of many investors, but do its r... Full story

Yahoo Finance • 21 days ago

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.

You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know about: It's a healthcare investor. Jo... Full story

Yahoo Finance • 27 days ago

Here's Why You Should Add ACET Stock to Your Portfolio Now

Adicet Bio ACET continues to make steady progress with prula-cel/prulacabtagene leucel (formerly known as ADI-001),the company's lead product candidate and primary clinical value driver in autoimmune diseases. It is a first-in-class invest... Full story

Yahoo Finance • 2 months ago

Lipocine Appoints Michael J. Grissinger to Board of Directors

SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the appointment... Full story

Yahoo Finance • 3 months ago

Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 28, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics... Full story

Yahoo Finance • 9 months ago

Adicet Bio Announces Reverse Stock Split

REDWOOD CITY, Calif., December 26, 2025--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today... Full story

Yahoo Finance • 10 months ago

Nutex Health Soars 21% After Hours On Revenue Surge; Biotech Peers Join Tuesday Gainers

(RTTNews) - Several small-cap biotech and pharma names posted notable gains in Tuesday's after-hours trading session, with Nutex Health standing out as the most significant mover following its quarterly results. Nutex Health Inc. (NUTX) s... Full story

Yahoo Finance • 11 months ago

Adicet Bio launches $80M securities offering

* Adicet Bio (NASDAQ:ACET [https://seekingalpha.com/symbol/ACET]) announced an underwritten direct offering of 70 million shares of common stock and, for certain investors, pre-funded warrants to buy 10 million shares. * The common sto... Full story

Yahoo Finance • 4 years ago

Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference

REDWOOD CITY, Calif. & BOSTON, February 01, 2023--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that... Full story

Yahoo Finance • 4 years ago

Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit

REDWOOD CITY, Calif. & BOSTON, November 30, 2022--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that... Full story

Yahoo Finance • 4 years ago

Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates

As of ASH abstract data-cut date, ADI-001 demonstrated a positive safety and efficacy profile; Company to provide more recent data cut from its ongoing Phase 1 study during ASH Annual Meeting Company to host ADI-001 webcast event on Decem... Full story

Yahoo Finance • 4 years ago

Adicet Bio to Present at Upcoming Investor Conferences

MENLO PARK, Calif. & BOSTON, May 18, 2022--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell the... Full story

Yahoo Finance • 4 years ago

Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates

Interim data from ADI-001 Phase 1 trial accepted for oral presentation at 2022 ASCO Annual Meeting Strong balance sheet with $277.9 million in cash and cash equivalents as of March 31, 2022 MENLO PARK, Calif. & BOSTON, May 12, 2022--(BUS... Full story

Yahoo Finance • 4 years ago

Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies

ADI-001 exhibited robust in vitro and in vivo tumor growth inhibition in multiple human lymphoma cell lines, with adaptive and innate mechanisms contributing to its anti-tumor activity Non-gene-edited ADI-001 gamma delta CAR T cells demon... Full story

Yahoo Finance • 4 years ago

Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

MENLO PARK, Calif. & BOSTON, April 27, 2022--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell t... Full story

Yahoo Finance • 4 years ago

Adicet Bio to Participate in Upcoming Investor Conferences

MENLO PARK, Calif., April 07, 2022--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies... Full story

Yahoo Finance • 4 years ago

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MENLO PARK, Calif. & BOSTON, April 01, 2022--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement... Full story